Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
6 Famous Urban communities for Shopping on the planet - 2Warning for snow and ice extended
- 3Step by step instructions to Pick an Incineration Urn: Variables to Consider
- 4Pick Your Number one sort of blossom
- 5AI is providing emotional support for employees – but is it a valuable tool or privacy threat?
- Putting pig organs in people is OK in the US, but growing human organs in pigs is not – why is that?
- Bismuth’s haredi draft bill won’t change enlistment, IDI expert tells 'Post'
- South Korea launches Earth-observation satellite on homegrown Nuri rocket
- The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices
- Unsold Rams May Be Less expensive Than You Suspect
- Embrace the Outside: Exercises and Entertainment
- Brazil's agricultural research agency gets cannabis research greenlight
- What is colostrum? And should you be taking it?
- US FDA declines to approve Corcept's drug for rare hormonal disorder
